Loading...

Expanding Radioisotope Production Will Fuel Global Personalized Medicine

Published
10 Feb 25
Updated
19 Sep 25
AnalystConsensusTarget's Fair Value
€22.85
24.0% undervalued intrinsic discount
19 Sep
€17.37
Loading
1Y
16.4%
7D
-5.2%

Author's Valuation

€22.85

24.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on19 Sep 25
Fair value Increased 5.46%

The upward revision in Eckert & Ziegler’s price target reflects modest improvements in both future P/E and net profit margin, resulting in a new consensus fair value of €22.85. What's in the News Confirmed 2025 earnings guidance with expected sales of approximately €320 million and EBIT before special items of about €78 million.

Shared on04 Sep 25

With no material changes in either the discount rate or future P/E ratio, analysts left Eckert & Ziegler’s fair value estimate effectively unchanged at €21.67. What's in the News Eckert & Ziegler confirmed 2025 guidance, expecting sales of around €320 million and EBIT before special items of around €78 million.

Shared on01 May 25
Fair value Decreased 66%

Shared on23 Apr 25
Fair value Decreased 0.24%

AnalystConsensusTarget has increased revenue growth from 7.8% to 9.1% and increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 9.37%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.80%

Shared on26 Mar 25
Fair value Increased 0.25%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on13 Mar 25
Fair value Decreased 3.90%

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.